Natriuretic peptide receptor 1 antibodies and methods of use

US11066469B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• John Diener · Cambridge, US
• Lars GADTKE · Munich, DE
• Felix HARTLEPP · Munich, DE
• Kathrin Ladetzki-Baehs · Planegg, DE
• Michael J. Romanowski · Foster City, US
• Cesare RUSSO · Basel, CH
• Xenia Wezler · Munich, DE

Key dates

• Filing date: Jun 10, 2020
• Grant date: Jul 20, 2021
• Expiry date: Jun 10, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This disclosure relates to anti-Natriuretic Peptide Receptor 1 (NPR1) antibodies including agonist antibodies which are able to activate the NPR1 receptor, pharmaceutical compositions comprising the same, and methods of treatment comprising the same.